ABBV Share Price | AbbVie, Inc. Stock Analysis & Recommendation

Q: Is AbbVie, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for AbbVie, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals across time frames. The Bollinger Bands show a mildly bullish stance on both weekly and monthly charts, and daily moving averages are also mildly bullish. However, the KST is bullish weekly but mildly bearish monthly, and Dow Theory reflects a mildly bearish weekly outlook against a bullish monthly view. In terms of performance, AbbVie has underperformed the S&P 500 over the past week and month, with returns of -5.32% and -7.70% respectively, while it has outperformed the benchmark year-to-date with a return of 21.49% compared to 16.30%. Overall, the current technical stance is mildly bullish, but with some caution due to mixed signals from various indicators.

Q: Is AbbVie, Inc. overvalued or undervalued?

As of 31 July 2025, the valuation grade for AbbVie, Inc. has moved from very expensive to risky, indicating a shift in perception regarding its valuation. Based on the current metrics, AbbVie appears to be overvalued. The P/E ratio stands at 23, while its peers, such as Eli Lilly & Co. with a P/E of 40.89 and Johnson & Johnson at 26.18, suggest that AbbVie is trading at a lower multiple compared to some competitors, yet still reflects a high valuation in its own right. Additionally, the EV to EBITDA ratio is 15.67, which is higher than Merck & Co. at 12.15, further supporting the notion of overvaluation.In terms of returns, AbbVie has outperformed the S&P 500 year-to-date with a return of 24.92% compared to the index's 12.22%. However, over the longer term, its 3-year return of 54.10% trails the S&P 500's 70.41%, indicating that while recent performance has been strong, it has not kept pace with broader market gains. Overall, AbbVie’s high valuation ratios and mixed performance relative to peers and the market suggest that it may be overvalued at its current price of 221.99.

Q: How big is AbbVie, Inc.?

As of Jun 18, AbbVie, Inc. has a market capitalization of 333,933.93 million, classifying it as a Large Cap company.As of the latest four quarters, AbbVie reported net sales of 57,367.00 million and a net profit of 4,163.00 million.As of Dec 24, the balance sheet shows shareholder's funds of 3,325.00 million and total assets amounting to 135,161.00 million.

Q: What does AbbVie, Inc. do?

Overview: AbbVie, Inc. is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and sale of pharmaceutical products, operating within the Pharmaceuticals & Biotechnology industry and classified as a large-cap company.Financial Snapshot: Most recent Net Sales: 13,343 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 1,279 Million (Quarterly Results - Mar 2025) Market cap: USD 333,933.93 Million (Large Cap)Key Metrics: P/E: 23.00 Dividend Yield: 251.41% Debt Equity: 45.57 Return on Equity: 1,031.47% Price to Book: 235.16Contact Details: Address: 1 N Waukegan Rd, NORTH CHICAGO IL: 60064-1802 Tel: 1 847 9327900 Website: https://www.abbvie.com/

Q: Who are in the management team of AbbVie, Inc.?

As of March 2022, the management team of AbbVie, Inc. includes Mr. Richard Gonzalez, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, Mr. Glenn Tilton is the Lead Independent Director. The board also comprises independent directors: Dr. Robert Alpern, Ms. Roxanne Austin, Mr. William Burnside, and Mr. Thomas Freyman.

Mojo Score Change: AbbVie, Inc. has changed its score on 05 Jun 2026. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.27 M

Shareholding (Mar 2026)

FII

16.59%

Held by 729 FIIs

DII

83.36%

Held by 168 DIIs

Promoter

0.04%

Is AbbVie, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, AbbVie, Inc. has a mildly bullish technical trend, with mixed signals from indicators, underperforming the S&P 500 recently but outperforming it year-to-date.

View full answer

Is AbbVie, Inc. overvalued or undervalued?

20-Sep-2025

As of July 31, 2025, AbbVie, Inc. is considered overvalued with a P/E ratio of 23 and an EV to EBITDA ratio of 15.67, despite a strong year-to-date return of 24.92%, as it has underperformed the S&P 500 over the past three years.

View full answer

How big is AbbVie, Inc.?

22-Jun-2025

As of Jun 18, AbbVie, Inc. has a market capitalization of approximately $333.93 billion, with net sales of $57.37 billion and a net profit of $4.16 billion over the last four quarters.

View full answer

What does AbbVie, Inc. do?

22-Jun-2025

AbbVie, Inc. is a large-cap biopharmaceutical company focused on the discovery, development, and sale of pharmaceutical products, with recent net sales of $13.34 billion and a market cap of approximately $333.93 billion. Key financial metrics include a P/E ratio of 23.00 and a dividend yield of 251.41%.

View full answer

Who are in the management team of AbbVie, Inc.?

22-Jun-2025

As of March 2022, AbbVie, Inc.'s management team includes Chairman and CEO Richard Gonzalez, Lead Independent Director Glenn Tilton, and independent directors Dr. Robert Alpern, Ms. Roxanne Austin, Mr. William Burnside, and Mr. Thomas Freyman.

View full answer

Compare AbbVie, Inc. with Similar Stocks

Johnson & Johnson Eli Lilly & Co.Merck & Co., Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Debt company with Weak Long Term Fundamental Strength

High Debt Company with a Debt to Equity ratio (avg) at times

Flat results in Jun 25

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 377,369 Million (Large Cap)

P/E

35.00

Industry P/E

Dividend Yield

3.11%

Debt Equity

-19.03

Return on Equity

-326.10%

Price to Book

-115.40

Revenue and Profits:

Net Sales:

15,002 Million

(Quarterly Results - Mar 2026)

Net Profit:

687 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-0.89%

6 Months

1.09%

1 Year

19.17%

2 Years

33.05%

3 Years

63.14%

4 Years

55.0%

5 Years

97.74%

AbbVie, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.95%

EBIT Growth (5y)

6.49%

EBIT to Interest (avg)

7.46

Debt to EBITDA (avg)

2.38

Net Debt to Equity (avg)

45.57

Sales to Capital Employed (avg)

0.79

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

281.66%

Pledged Shares

Institutional Holding

76.07%

ROCE (avg)

25.94%

ROE (avg)

300.50%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

-115.40

EV to EBIT

21.91

EV to EBITDA

15.55

EV to Capital Employed

7.46

EV to Sales

7.19

PEG Ratio

Dividend Yield

3.11%

ROCE (Latest)

34.04%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 264 Schemes (29.85%)

Foreign Institutions

Held by 729 Foreign Institutions (16.59%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 12.43% vs 8.39% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -46.29% vs -6.09% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15,002.00",
          "val2": "13,343.00",
          "chgp": "12.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6,961.00",
          "val2": "6,036.00",
          "chgp": "15.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "760.00",
          "val2": "739.00",
          "chgp": "2.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3,397.00",
          "val2": "-1,807.00",
          "chgp": "-87.99%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "687.00",
          "val2": "1,279.00",
          "chgp": "-46.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "335.00%",
          "val2": "299.60%",
          "chgp": "3.54%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 8.57% vs 3.71% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -1.25% vs -12.09% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "61,160.00",
          "val2": "56,334.00",
          "chgp": "8.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "29,052.00",
          "val2": "25,011.00",
          "chgp": "16.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3,059.00",
          "val2": "2,954.00",
          "chgp": "3.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-12,671.00",
          "val2": "-11,187.00",
          "chgp": "-13.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4,193.00",
          "val2": "4,246.00",
          "chgp": "-1.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "341.90%",
          "val2": "295.10%",
          "chgp": "4.68%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

15,002.00

13,343.00

12.43%

Operating Profit (PBDIT) excl Other Income

6,961.00

6,036.00

15.32%

Interest

760.00

739.00

2.84%

Exceptional Items

-3,397.00

-1,807.00

-87.99%

Consolidate Net Profit

687.00

1,279.00

-46.29%

Operating Profit Margin (Excl OI)

335.00%

299.60%

3.54%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 12.43% vs 8.39% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -46.29% vs -6.09% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

61,160.00

56,334.00

8.57%

Operating Profit (PBDIT) excl Other Income

29,052.00

25,011.00

16.16%

Interest

3,059.00

2,954.00

3.55%

Exceptional Items

-12,671.00

-11,187.00

-13.27%

Consolidate Net Profit

4,193.00

4,246.00

-1.25%

Operating Profit Margin (Excl OI)

341.90%

295.10%

4.68%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 8.57% vs 3.71% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -1.25% vs -12.09% in Dec 2024

All Annual Results

Company CV

About AbbVie, Inc.

AbbVie, Inc.

Pharmaceuticals & Biotechnology

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Company Coordinates

Company Details

1 N Waukegan Rd , NORTH CHICAGO IL : 60064-1802

Tel: 1 847 9327900

https://www.abbvie.com/

Registrar Details